harris rotman headshot grayscale

Harris Rotman PhD

Senior Vice President, Regulatory Affairs.

Dr. Harris Rotman joined Centessa in July 2022 as Senior Vice President, Regulatory Affairs. Dr. Rotman has over twenty years of pharmaceutical industry experience with an additional eight years of scientific research training. He has experience liaising with various regulatory agencies, and is proficient in investigational development, post-approval activities, application maintenance, advertising/promotion review, and medical writing. Dr. Rotman has managed multiple worldwide developmental projects for regulatory in neuroscience, cardiovascular, renal, dermatologic, analgesic, addiction, aesthetic, and gastrointestinal therapeutic areas, including rare/orphan disease products. He has worked at Wyeth, Sanofi, Shire, Indivior, Endo, and SwanBio Therapeutics.

Dr. Rotman received his BS in Biological Sciences from Rutgers University and PhD in Microbiology and Molecular Virology from Thomas Jefferson University. He then did his Postdoctoral Fellowship at Hahnemann University Hospital.

Back to Executive Team
Scroll to Top
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678, NCT05789524, NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B